Vaccine will generate 73% more than forecast based on contracts signed until mid-April

US drugmaker Pfizer expects to make $26bn (£19bn) in revenues from sales of its Covid-19 vaccine this year, with its soaraway product accounting for more than a third of the company’s annual income.

The vaccine, which was developed with Germany’s BioNTech, contributed $3.5bn in global revenues at Pfizer in the first three months of the year, and the company had expected it to bring in $15bn over the course of 2021.

Continue reading...
Tuesday, May 4, 2021 - 9:12am